Zanaletti et al. developed a new α7 nicotinic acetylcholine receptors (α7 nAChR) represented promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer’s disease (AD) and schizophrenia. This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.